Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at Jefferies Financial Group issued their Q3 2019 EPS estimates for Abeona Therapeutics in a report issued on Wednesday, March 20th, Zacks Investment Research reports. Jefferies Financial Group analyst M. Raycroft expects that the biopharmaceutical company will post earnings of ($0.38) per share for the quarter. Jefferies Financial Group also issued estimates for Abeona Therapeutics’ Q4 2019 earnings at ($0.48) EPS.
ABEO has been the subject of several other research reports. BidaskClub lowered shares of Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 22nd. Cantor Fitzgerald set a $29.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 19th. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 6th. ValuEngine raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Abeona Therapeutics in a report on Thursday, February 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $26.00.
A number of large investors have recently modified their holdings of the stock. Parkside Advisors LLC raised its position in Abeona Therapeutics by 16.0% in the 4th quarter. Parkside Advisors LLC now owns 14,530 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,000 shares during the period. SG Americas Securities LLC raised its position in Abeona Therapeutics by 23.7% in the 4th quarter. SG Americas Securities LLC now owns 22,720 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 4,351 shares during the period. Geode Capital Management LLC increased its position in shares of Abeona Therapeutics by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 341,206 shares of the biopharmaceutical company’s stock valued at $2,436,000 after acquiring an additional 6,826 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Abeona Therapeutics by 247.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,194 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 7,258 shares during the period. Finally, Allianz Asset Management GmbH increased its position in shares of Abeona Therapeutics by 9.4% in the third quarter. Allianz Asset Management GmbH now owns 110,649 shares of the biopharmaceutical company’s stock valued at $1,416,000 after acquiring an additional 9,465 shares during the period. Institutional investors own 67.91% of the company’s stock.
In other Abeona Therapeutics news, Director Stephen B. Howell bought 4,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $7.77 per share, for a total transaction of $31,080.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Stefano Buono bought 70,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $7.80 per share, for a total transaction of $546,000.00. Following the transaction, the director now owns 20,980 shares in the company, valued at $163,644. The disclosure for this purchase can be found here. 6.70% of the stock is owned by company insiders.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Further Reading: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.